A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults

Trial Profile

A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs RSV F protein vaccine-Novavax (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms Resolve
  • Sponsors Novavax
  • Most Recent Events

    • 10 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 15 Sep 2016 Primary endpoint has not been met. (Numbers and percentages of subjects with moderate-severe RSV-LRTD), according to a Novavax Inc. media release.
    • 15 Sep 2016 Results published in the Novavax Inc. Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top